|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions increases response to substance |
ISO |
9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine]; Quercetin inhibits the reaction [SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog] SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine; SLC22A6 protein results in increased susceptibility to 9-((2-phosphonylmethoxy)ethyl)guanine analog |
CTD |
PMID:23856525 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of BIRC3 protein] |
CTD |
PMID:25125499 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein] |
CTD |
PMID:25125499 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of CFLAR mRNA] lysophosphatidylethanolamine analog results in increased expression of CFLAR protein Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein] lysophosphatidylethanolamine analog results in increased expression of CFLAR mRNA; lysophosphatidylethanolamine analog results in increased expression of CFLAR protein |
CTD |
PMID:25125499 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[lysophosphatidylethanolamine analog co-treated with cobaltous chloride] results in increased phosphorylation of GSK3B protein |
CTD |
PMID:25125499 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions increases expression |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in decreased expression of and results in increased degradation of MCL1 protein] lysophosphatidylethanolamine analog results in increased expression of MCL1 protein lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein] |
CTD |
PMID:25125499 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine; [NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of lysophosphatidylethanolamine analog |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
lysophosphatidylethanolamine analog inhibits the reaction [cobaltous chloride results in increased activity of PARP1 protein] |
CTD |
PMID:25125499 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine |
CTD |
PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases abundance |
ISO |
AHR protein results in decreased abundance of phosphatidylethanolamine |
CTD |
PMID:29416063 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
phosphatidylethanolamine results in increased stability of and results in increased activity of CYP1A2 protein |
CTD |
PMID:15966743 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases abundance |
ISO |
FGF19 protein results in increased abundance of phosphatidylethanolamine |
CTD |
PMID:29416063 |
|
NCBI chr 1:200,056,656...200,059,944
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]]; dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine] |
CTD |
PMID:19848398 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases abundance |
ISO |
PPARGC1B results in increased abundance of phosphatidylethanolamine |
CTD |
PMID:17932310 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions affects binding |
ISO |
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to phosphatidylethanolamine] |
CTD |
PMID:15313215 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to phosphatidylethanolamine] |
CTD |
PMID:15313215 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] [Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:15901796 PMID:19853032 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects secretion increases expression |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the secretion of Rosuvastatin Calcium [Benzbromarone results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Probenecid results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Sulfasalazine results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Rosuvastatin Calcium promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] Rosuvastatin Calcium results in increased expression of ABCC2 protein |
CTD |
PMID:19853032 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCG1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases activity |
EXP ISO |
[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium Rosuvastatin Calcium results in increased activity of ABCG2 protein |
CTD |
PMID:19853032 PMID:30083819 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[Piracetam co-treated with Rosuvastatin Calcium] inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]; Rosuvastatin Calcium inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein] |
CTD |
PMID:28441890 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
Rosuvastatin Calcium affects the phosphorylation of AKT1 protein |
CTD |
PMID:27815113 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions increases expression |
ISO |
Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein] |
CTD |
PMID:12767421 PMID:15539964 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of APOB protein |
CTD |
PMID:15539964 PMID:18702965 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of BAX mRNA] |
CTD |
PMID:32007421 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of BCL2 protein |
CTD |
PMID:20852871 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of C3 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO |
Rosuvastatin Calcium results in increased activity of CASP3 protein Rosuvastatin Calcium results in increased expression of CASP3 protein |
CTD |
PMID:21478229 PMID:32771489 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Rosuvastatin Calcium results in increased activity of CAT protein [Rosuvastatin Calcium co-treated with Isoproterenol] inhibits the reaction [Interleukin-6 results in increased expression of CAT protein]; Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased activity of CAT protein] |
CTD |
PMID:20146376 PMID:32007421 PMID:35130744 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of CCL2 mRNA |
CTD |
PMID:15681303 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of CREB5 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3] |
CTD |
PMID:21562509 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions decreases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA] [[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:16633368 PMID:21562509 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ESR1 protein |
CTD |
PMID:32771489 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of GCLC mRNA [Tetradecanoylphorbol Acetate co-treated with Rosuvastatin Calcium] results in increased expression of GCLC mRNA |
CTD |
PMID:18154958 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gzmk |
granzyme K |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GZMK mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases secretion |
ISO |
HNF4A protein results in increased secretion of Rosuvastatin Calcium |
CTD |
PMID:27160211 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of IL1B mRNA |
CTD |
PMID:15681303 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Rosuvastatin Calcium results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of KCNJ15 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of KDR protein] |
CTD |
PMID:27097221 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mb |
myoglobin |
affects expression |
EXP |
Rosuvastatin Calcium affects the expression of MB protein |
CTD |
PMID:27815113 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Rosuvastatin Calcium results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,453,982...48,458,809
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in increased expression of NOS2 mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of NOS2 mRNA] |
CTD |
PMID:21443142 PMID:32007421 PMID:35130744 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions affects response to substance increases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]; Rosuvastatin Calcium results in increased phosphorylation of and results in increased activity of NOS3 protein NOS3 protein affects the susceptibility to Rosuvastatin Calcium Rosuvastatin Calcium results in increased expression of NOS3 mRNA |
CTD |
PMID:12354446 PMID:15681303 PMID:18162361 PMID:21562509 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions decreases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ORM1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PECAM1 protein] |
CTD |
PMID:27097221 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Selp |
selectin P |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of SELP mRNA |
CTD |
PMID:15681303 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpine2 |
serpin family E member 2 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SERPINE2 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] |
CTD |
PMID:27097221 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases expression affects transport |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] Rosuvastatin Calcium results in decreased expression of SLCO1A4 protein SLCO1A4 protein affects the transport of Rosuvastatin Calcium |
CTD |
PMID:19833843 PMID:24909372 PMID:26888941 PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases uptake |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:26888941 PMID:31299240 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of TFF1 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] Rosuvastatin Calcium results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15681303 PMID:27097221 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in decreased expression of TNF mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNF protein] |
CTD |
PMID:15681303 PMID:32007421 PMID:35130744 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNNI3 protein] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Vnn3 |
vanin 3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of VNN3P mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 1:21,571,364...21,583,626
Ensembl chr 1:21,571,364...21,583,626
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|